PAR-19-264: Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional)

NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional) PAR-19-264. NCI

Read the full article here

Related Articles